Chelsea K. Osterman

Chelsea K. Osterman

Auto-generated profile, based on publicly available information

Chelsea K. Osterman

University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TRTracy L. Rose
Tracy L. Rose
MHMichael R. Harrison
Michael R. Harrison
ADAllison Deal
Allison Deal
SRSundhar Ramalingam
Sundhar Ramalingam
Young E. WhangYoung E. Whang
Young E. Whang
MMMatthew I Milowsky
Matthew I Milowsky
PURPOSE: To evaluate the safety and efficacy of gemcitabine and cisplatin in combination with the immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical cystectomy (RC) in muscle-invasive bladder cancer. METHODS: Patients with clinical T2-4aN0/XM0 muscle-invasive bladder cancer eligible for RC were enrolled. The initial six patients received lead-in pembrolizumab 200 mg once 2 weeks prior to pembrolizumab 200 mg once on day 1, cisplatin 70 mg/m2 once on day 1, and gemcitabine 1,000 mg/m2 once on days 1 and 8 every 21 days for four cycles. This schedule was discontinued for toxicity and subsequent patients received cisplatin 35 mg/m2 once on days 1 and 8 without lead-in pembrolizumab. The primary end point was pathologic downstaging (< pT2N0) with null and alternative hypothesis rates of 35% and 55%, respectively. Secondary end points were toxicity including patient-reported outcomes, complete pathologic response (pT0N0), event-free survival, and overall survival. Association of pathologic downstaging with programmed cell death ligand 1 staining was explored. RESULTS: Thirty-nine patients were enrolled between June 2016 and March 2020 (72% cT2, 23% cT3, and 5% cT4a). Patients received a median of four cycles of therapy. All patients underwent RC except one who declined. Twenty-two of 39 patients (56% [95% CI, 40 to 72]) achieved < pT2N0 and 14 of 39 (36% [95% CI, 21 to 53]) achieved pT0N0. Most common adverse events (AEs) of any grade were thrombocytopenia (74%), anemia (69%), neutropenia (67%), and hypomagnesemia (67%). One patient had new-onset type 1 diabetes mellitus with ketoacidosis related to pembrolizumab and no patients required steroids for immune-related AEs. Clinicians consistently under-reported AEs when compared with patients. CONCLUSION: Neoadjuvant gemcitabine and cisplatin plus pembrolizumab met its primary end point for improved pathologic downstaging and was generally safe. A global study of perioperative chemotherapy plus pembrolizumab or placebo is ongoing.

25 February 2015 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
COChelsea Osterman
Chelsea Osterman
MMMary Beth R. McCarthy
Mary Beth R. McCarthy
MCMark P. Cote
Mark P. Cote
KBKnut Beitzel
Knut Beitzel
JBJames Bradley
James Bradley
AMAugustus D. Mazzocca
Augustus D. Mazzocca
Background: Platelet-rich plasma (PRP) has anti-inflammatory effects with potential applications in the treatment of osteoarthritis (OA). Purpose: To use an in vitro coculture model of OA in human cartilage and synovium to investigate the anti-inflammatory effects of 2 different PRP preparations. Study Design: Controlled laboratory study. Methods: A coculture system was created using osteoarthritic cartilage and synovium from 9 patients undergoing total knee arthroplasty. Interleukin-1β (IL-1β) was added to each coculture to induce inflammation. Two PRP preparations were obtained—one yielding low white blood cell and platelet concentrations (PRP LP ) and one yielding high platelet and white blood cell concentrations (PRP HP ). Either PRP LP , PRP HP , or medium was added to the coculture wells. Control wells contained OA cartilage and synovium but neither IL-1β nor PRP. Normal, non-OA cartilage was obtained to establish baseline gene expression levels. Quantitative polymerase chain reaction was used to measure changes in markers of inflammation in the tissues (a disintegrin and metalloproteinase with thrombospondin motifs–5 [ADAMTS-5], tissue inhibitor of metalloproteinases–1 [TIMP-1], vascular endothelial growth factor [VEGF], aggrecan, and type I collagen) at 0, 24, 48, and 72 hours. Results: Treatment with PRP LP or PRP HP significantly decreased expression of TIMP-1 and ADAMTS-5 in cartilage, increased aggrecan expression in cartilage, and decreased ADAMTS-5, VEGF, and TIMP-1 expression in synovium compared with control cocultures ( P < .05). There was significantly less nitric oxide production in the PRP LP and PRP HP groups compared with controls ( P < .05). There were significant differences in gene expression in the normal cartilage compared with all 4 groups of OA cartilage at all 4 time points. Treatment with either PRP LP or PRP HP returned some gene expression to the same levels in normal cartilage but not for all markers of inflammation. Conclusion: This coculture model assessed 2 different PRP preparations and their anti-inflammatory effects over time on human OA cartilage and synovium. Both had a significant anti-inflammatory effect on gene expression; however, there was no difference in the anti-inflammatory effect between the 2 preparations. Clinical Relevance: Osteoarthritis is a leading cause of chronic disability, and less invasive treatment methods are needed. Study results suggest that PRP injections may be an effective alternative anti-inflammatory agent in the treatment of OA.

1 September 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
COChelsea K. Osterman
Chelsea K. Osterman
HSHanna K. Sanoff
Hanna K. Sanoff
WWWilliam Wood
William Wood
MFMegan Fasold
Megan Fasold
JLJennifer A. Elston Lafata
Jennifer A. Elston Lafata
Emergency department visits and hospitalizations are common among people receiving cancer treatment, accounting for a large proportion of spending in oncology care and negatively affecting quality of life. As oncology care shifts toward value- and quality-based payment models, there is a need to develop interventions that can prevent these costly and low-value events among people receiving cancer treatment. Risk stratification programs have the potential to address this need and optimally would consist of three components: (1) a risk stratification algorithm that accurately identifies patients with modifiable risk(s), (2) intervention(s) that successfully reduce this risk, and (3) the ability to implement the risk algorithm and intervention(s) in an adaptable and sustainable way. Predictive modeling is a common method of risk stratification, and although a number of predictive models have been developed for use in oncology care, they have rarely been tested alongside corresponding interventions or developed with implementation in clinical practice as an explicit consideration. In this article, we review the available published predictive models for treatment-related toxicity or acute care events among people receiving cancer treatment and highlight challenges faced when attempting to use these models in practice. To move the field of risk-stratified oncology care forward, we argue that it is critical to evaluate predictive models alongside targeted interventions that address modifiable risks and to demonstrate that these two key components can be implemented within clinical practice to avoid unplanned acute care events among people receiving cancer treatment.

6 February 2019 in The Oncologist
Verified
Journal Article
Open access
PDF file
COChelsea K. Osterman
Chelsea K. Osterman
DBDilip S. Babu
Dilip S. Babu
DGDaniel M. Geynisman
Daniel M. Geynisman
BLBianca Lewis
Bianca Lewis
RSRobert A. Somer
Robert A. Somer
RMRonac Mamtani
Ronac Mamtani
Neoadjuvant cisplatin-based chemotherapy (NAC; 70 mg/m2) is standard of care for muscle-invasive bladder carcinoma (MIBC). Many patients (pts) cannot receive cisplatin because of renal impairment, and administration of cisplatin 35 mg/m2 on day 1 + 8 or 1 + 2 (i.e., split schedule) is a commonly used alternative. In this retrospective analysis, we compared complete (pT0) and partial (<pT2) pathologic response rates between split schedule (SS) and conventional schedule (CS) pts, after 1:1 matching on chemotherapy regimen, number of cycles, tumor histology, and clinical stage. Eighty matched pts were identified. pT0 rates were 17.5% (95% confidence interval [CI], 7%–33%) and 32.5% (95% CI, 19%–49%) in SS and CS cisplatin pts, respectively (p = .21), corresponding to an odds ratio for pT0 of 0.45 (95% CI, 0.16–1.31) with SS cisplatin. Split schedule cisplatin was associated with numerically but not statistically significant lower pathologic response rates relative to full dose.

27 July 2020 in Journal of Urology
Verified
Journal Article
Closed access
COChelsea K. Osterman
Chelsea K. Osterman
ADAllison M. Deal
Allison M. Deal
HMHannah McCloskey
Hannah McCloskey
KNKirsten A. Nyrop
Kirsten A. Nyrop
MBMarc A. Bjurlin
Marc A. Bjurlin
ASAngela B. Smith
Angela B. Smith
Purpose: Treatment for muscle invasive bladder cancer includes radical cystectomy, a major surgery that can be associated with significant toxicity. Limited data exist related to changes in patient global health status and recovery following radical cystectomy. We used geriatric assessment to longitudinally compare health related impairments in older and younger patients with muscle invasive bladder cancer who undergo radical cystectomy. Materials and Methods: Older and younger patients (70 or older and younger than 70 years) with muscle invasive bladder cancer undergoing radical cystectomy at an academic institution were enrolled between 2012 and 2019. Patients completed the geriatric assessment before radical cystectomy, and 1, 3 and 12 months after radical cystectomy. For each geriatric assessment measure the Wilcoxon rank sum test was used to compare score distribution between age groups at each time point. The Wilcoxon signed rank test was used to compare distributions between time points within each age group. Results: A total of 80 patients (42 younger and 38 older) were enrolled. Before radical cystectomy 78% of patients were impaired on at least 1 geriatric assessment measure. Both age groups had worsening physical function and nutrition at 1 month after radical cystectomy, with older patients having a greater decline in function than younger patients. Both groups recovered to baseline at 3 months after radical cystectomy and maintained this status at 1 year. Conclusions: High rates of impairments were found across age groups in the short term after radical cystectomy, followed by recovery to baseline.

1 June 2018 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
COChelsea K. Osterman
Chelsea K. Osterman
JAJaber Alanzi
Jaber Alanzi
JLJames D. Lewis
James D. Lewis
EKElizabeth L. Kaufman
Elizabeth L. Kaufman
VNVivek Narayan
Vivek Narayan
RMRonac Mamtani
Ronac Mamtani